{"id":"W2583641997","doi":"10.1016/s1470-2045(17)30003-7","title":"Adjuvant ipilimumab for stage III melanoma: the patient voice","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Melanoma; Discontinuation; Placebo; Adverse effect; Oncology; Adjuvant; Adjuvant therapy; Hazard ratio; Cancer; Gastroenterology; Immunotherapy; Pathology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001588887,0.0004451706,0.001012248,0.0003416792,0.001624841,0.002203761,0.0006860894,0.02020973,0.003813128],"category_scores_gemma":[0.01090209,0.0003347011,0.0007068272,0.0002949872,0.001556858,0.002596058,0.001165218,0.01941678,0.002823477],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002296111,"about_ca_system_score_gemma":0.00171519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009750931,"about_ca_topic_score_gemma":0.002896625,"domain_scores_codex":[0.9988605,0.0003959946,0.000108345,0.0001059832,0.0003164813,0.0002126659],"domain_scores_gemma":[0.9971687,0.001713522,0.0002271445,0.00007699747,0.0002638619,0.0005497146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"qualitative","study_design_scores_codex":[0.0002655851,0.00007313125,0.001677263,0.0001202136,0.0000320503,0.01143213,0.0001998669,0.0002183787,0.0008088953,0.006603183,0.9305212,0.04804809],"study_design_scores_gemma":[0.0005239109,0.0003854634,0.001825492,0.0006325007,0.00007974776,0.02200399,0.00065281,0.001391895,0.0006799296,0.03471662,0.9370292,0.00007850015],"study_design_candidate":"qualitative","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.001239874,0.003484364,0.00009305187,0.9817774,0.01036262,0.0000058935,0.00003212825,0.00001362116,0.002991131],"genre_scores_gemma":[0.02499343,0.00613209,0.000305777,0.8770009,0.08331022,0.00002480933,0.0000562961,0.0000313727,0.008145151],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02020973,"threshold_uncertainty_score":0.0166595,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06020058253608758,"score_gpt":0.3461598513023324,"score_spread":0.2859592687662448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}